Continuing rise. It was announced that after the market closed yesterday, a patent for new treatment applications related to cardiomyopathy and associated chronic heart failure, utilizing the regenerative-inducing drug ledasemtide (a peptide drug created from HMGB1), has been registered in Europe. This patent aims to expand the range of indications for ledasemtide. With the establishment of this patent, it can ensure the possibility of developing treatments using ledasemtide for cardiomyopathy and chronic heart failure resulting from it in the European region.
ステムリム---続伸、再生誘導医薬レダセムチドを用いた心筋症治療などが欧州で特許登録
Stem Inc --- continued growth, patent registration in Europe for the treatment of cardiomyopathy using the regenerative medicine Redasemtide, etc.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated